Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Dec 7, 1999
Grant Date -
N/A
app pub date -
Sep 19, 1997
filing date -
Sep 19, 1997
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The present invention is directed to reduce elevated levels of tumor necrosis factor-alpha (TNF-.alpha.) found in a failing heart. The present invention is directed to a composition and method of regulating TNF-.alpha. expression in myocardial tissue by treating the myocardial tissue with biological equivalents of endogenous adenosine. A composition and method of using the composition to treat patients with damaged myocardial tissue is provided which increases the cellular availability of adenosine with a resulting decrease of TNF-.alpha. levels in the heart. The present invention provides a novel pharmacological intervention program in failing mammalian hearts, and more particularly provides a cardioprotective treatment to patients with congestive heart failure.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully